New cancer drug trial tests immune system booster for tough tumors
NCT ID NCT05070247
Summary
This study tested a new drug called TAK-500, designed to activate the immune system to fight cancer. It was given alone or combined with an existing immunotherapy drug (pembrolizumab) to adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to find a safe dose and see if the treatment could shrink tumors in cancers like lung, pancreatic, and kidney cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Comprehensive Cancer Center
Duarte, California, 91010, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111, United States
-
New York University
New York, New York, 10016-4744, United States
-
Northwestern
Chicago, Illinois, 60611, United States
-
START South Texas Accelerated Research Therapeutics
San Antonio, Texas, 78229, United States
-
Sarah Cannon Cancer Institute
Nashville, Tennessee, 37203, United States
-
Sarah Cannon Research Institute
Denver, Colorado, 80218, United States
-
Sylvester Comprehensive Cancer Center
Miami, Florida, 33136, United States
-
Univeristy of Alabama at Birmingham
Birmingham, Alabama, 35294, United States
-
University of California San Diego
La Jolla, California, 92093, United States
-
University of Colorado - Anschutz Medical Campus - PPDS
Aurora, Colorado, 80045, United States
Conditions
Explore the condition pages connected to this study.